Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAPI: Allo-hMSCs in Cystic Fibrosis
NCT03058068Phase 1Withdrawn
- Start
- Dec 2020
- Primary completion
- Sep 2027
- Modality
- Stem Cell Therapies
01
Overview
Phase 1, randomised, double-blind trial of allogeneic bone marrow-derived human mesenchymal stem cells in cystic fibrosis (CF) (5 arms). Primary endpoint: Treatment-Emergent Serious Adverse Events at 30 days. Planned start Dec 2020; status: withdrawn.
02
Drugs
allogeneic bone marrow-derived human mesenchymal stem cells
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03058068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03058068.